摘要
Objective To evaluate the efficacy and prognostic factors in core binding factor (CBF) acute myeloid leukemia (AML) under current therapy modalities,therefore optimizing the treatment strategies.Methods Standard cytological and immune methods including next generation sequencing (NGS) were used for risk stratification.
作者
WANG Biao
王彪(Dept Hematol,Changzhou 1st People's Hosp,Changzhou 213000)
